Top 5 Future Oncology articles – May 2021

Written by Louis Gautier, Future Science Group

Future Oncology February issue

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares his top 5 picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis’ highlights below. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial  The results of the ARAMIS trial were published in September of 2020, reporting that darolutamide (Nubeqa®) in combination with hormone therapy was effective at prolonging survival and decreased the risk of death from nonmetastatic, castration-resistant prostate cancer by 31% compared with placebo.  This open access plain language summary reports the...

To view this content, please register now for access

It's completely free